Glenmark targets US revenue above $430m in FY27 as margins expand
Glenmark Pharmaceuticals expects its US business to grow 10–12% annually and exceed $430 million in FY27, supported by respiratory launches and the Monroe plant. The company retained its 21–22% full-year EBITDA-margin guidance after Q1 revenue rose 23.1% year on year.
What happened
Glenmark Pharmaceuticals · Glenmark expects FY27 US revenue above $430 million and sustained 10–12% annual growth, supported by respiratory launches and its
Key facts
- FY27 US revenue expected to exceed $430 million
- US business growth expected at 10–12% annually
- US business contributed 22–25% of overall business
- Q1 FY27 revenue rose 23.1% YoY to ₹4,018 crore
- Q1 FY27 EBITDA rose 38.6% YoY to ₹804.7 crore
- Q1 FY27 EBITDA margin was 20%, versus 17.8%
- Q1 FY27 net profit was ₹482.8 crore versus ₹47 crore
- India revenue grew around 15.5%
- Full-year EBITDA margin guidance: 21–22%
- India growth guidance: 12–15%
Why this matters
Glenmark’s expanding US respiratory portfolio and manufacturing platform make it a more consequential partner or competitor in specialty and generic pharmaceutical markets.
What to watch
- Quarterly US revenue growth relative to the stated 10-12% annual target.
- FDA approvals, launch dates and competitive intensity for respiratory products.
- Monroe plant utilization, inspection outcomes, remediation costs and supply reliability.
- US generic pricing, wholesaler inventory movements, chargebacks and customer concentration trends.
- EBITDA-margin progression versus the 21-22% full-year guidance range.
- Any revision to FY27 US revenue guidance, especially evidence that revenue can exceed $430 million earlier than planned.
- Prioritize US respiratory launches and payer/channel contracting to secure formulary access before competing generic entries.
- Increase Monroe plant utilization and product transfers to improve manufacturing absorption and reduce supply-chain dependence.
- Allocate incremental US cash flow toward complex respiratory, dermatology and specialty-development assets rather than low-margin commodity generics.
- Use sustained margin delivery to strengthen investor messaging around a higher-quality US earnings mix and potential balance-sheet improvement.